WVWinnie G. Vos

Winnie G. Vos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Winnie G. Vos has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Esther Lutgens

    Univ Amsterdam, Amsterdam UMC, Locat AMC, Dept Med Biochem, Amsterdam, Netherlands

    3 shared publications
  • Laura A. Bosmans

    Amsterdam University Medical Centre

    3 shared publications
  • Wietse In Het Panhuis

    Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    2 shared publications
  • Aldo Grefhorst

    Department of Experimental Vascular Medicine, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands

    1 shared publication
  • Amanda C.M. Pronk

    Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands

    1 shared publication
  • Begoña Porteiro

    Univ Amsterdam, Amsterdam Univ Med Ctr, Tytgat Inst Liver & Intestinal Res, Amsterdam, Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Peritoneal Dialysis Aggravates and Accelerates Atherosclerosis in Uremic ApoE −/− Mice

    by Jamie Kane, Winnie G. Vos, Laura A. Bosmans, Bram W. van Os, Myrthe Den Toom, Sanne Hoeksema‐Hackmann, Denise Moen‐De Wit, Marion J. Gijbels, Linda Beckers, Aldo Grefhorst, et al.

    Background: Atherosclerosis is highly prevalent in people with chronic kidney disease (CKD), including those receiving peritoneal dialysis (PD). Although it is lifesaving, PD induces profound systemic inflammation, which may aggravate atherosclerosis. Therefore, the hypothesis is that this PD‐induced inflammation aggravates atherosclerosis via immune cell activation. Methods and Results: ApoE −/− mice were subjected to a 5/6 nephrectomy to induce CKD. Three weeks later, mice were fed a high‐cholesterol diet. Half of the nephrectomized mice then received daily peritoneal infusions of 3.86% Physioneal for 67 further days (CKD+PD) until the end of the experiment, and were compared with mice without CKD. Sham operated and PD‐only mice were additional controls. CKD+PD mice displayed more severe atherosclerotic disease than control mice. Plaque area increased, and plaques were more advanced with a vulnerable phenotype typified by decreased collagen content and decreased fibrous cap thickness. Increased CD3 + T‐cell numbers were present in plaques and perivascular adipose tissue of CKD and CKD+PD mice. Plaques of CKD+PD mice contained more iNOS + immune cells. Spleens of CKD+PD mice showed more CD4 + central memory, terminally differentiated type 1 T‐helper (Th1), Th17, and CX3C motif chemokine receptor 1 + (CX3CR1) CD4 + T‐cells with less regulatory and effector T‐cells. Conclusions: PD‐fluid exposure in uremic mice potentiates systemic and vascular T‐cell‐driven inflammation and aggravates atherosclerosis. PD polarized CD4 + T‐cells toward an inflammatory Th1/Th17 phenotype, and increased CX3CR1 + CD4 + T‐cells, which are associated with vascular homing in CKD‐associated atherosclerosis. Targeting CD4 + T‐cell activation and CX3CR1 + polarization has the potential to attenuate atherosclerosis in PD patients.


  • Open Access

    Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1 Ldlr mice

    by Begoña Porteiro, Reinout L.P. Roscam Abbing, Wietse In Het Panhuis, Dirk R. de Waart, Suzanne Duijst, Isabelle Bolt, Esther W. Vogels, Johannes H.M. Levels, Laura A. Bosmans, Winnie G. Vos, et al.


  • Open Access

    Time-restricted feeding attenuates hypercholesterolaemia and atherosclerosis development during circadian disturbance in APOE∗3-Leiden.CETP mice

    by Wietse In Het Panhuis, Milena Schönke, Melanie Modder, Hannah E. Tom, Reshma A. Lalai, Amanda C.M. Pronk, Trea C.M. Streefland, Linda W.M. van Kerkhof, Martijn E.T. Dollé, Marie A.C. Depuydt, et al.


  • Open Access

    Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?

    by Winnie G Vos, Esther Lutgens, Tom T P Seijkens

    In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI efficacy are therefore needed. The widespread clinical use of ICIs has increased our knowledge on the effects of the concomitant use of commonly prescribed drugs on the outcome of ICI treatment. A particular interesting class of drugs in this context are statins. These HMG-CoA reductase inhibitors, which are used to treat hypercholesterolemia and reduce the risk for atherosclerotic cardiovascular disease, are frequently used by patients with (advanced) cancer. This paper addresses the hypothesis that statins improve the efficacy of ICI therapy.